LEO Pharma Appoints Barbara Osborne As President & CEO Of LEO U.S. Region

PARSIPPANY, New Jersey, November 19, 2014 /PRNewswire/ --

LEO Pharma Inc. announced it has named Barbara J. Osborne as President and Chief Executive Officer (CEO) of LEO Pharma U.S. Region. She will serve on the LEO Pharma Global Management Team.

(Logo: http://photos.prnewswire.com/prnh/20130221/595427 )

(Photo: http://photos.prnewswire.com/prnh/20141119/717598 )

Ms. Osborne is a highly qualified health-care industry executive with extensive medical device experience who at her last organization successfully led its growth in sales moving its U.S. division from the #5 position in the country to being the market leader.

"I am confident that the strong LEO U.S. team will benefit from her leadership and extensive experience from successfully leading and growing U.S. organizations enabling our U.S. business to grow to the benefit of first and foremost our patients," says Lars Olsen, Executive Vice President, Global Sales & Marketing.

Ms. Osborne stated, "I am delighted to be joining LEO Pharma at such a paramount stage of its patient-centric development and feel fortunate to be given the opportunity to continue to build and grow the LEO U.S. Region from its present foundation."

Prior to joining LEO U.S. and since 2011, Ms. Osborne served as President and CEO at Mölnlycke Health Care's U.S. Wound Care Division, based in Atlanta, Georgia. Under her leadership, she significantly increased business sales and profitability. Before her role as president, Ms. Osborne held the position as Vice President of Sales at Mölnlycke when she joined the organization in 2007.

Ms. Osborne has a broad background encompassing managing sales, marketing, finance, accounting and R&D. During her 27 years in the healthcare industry, she held positions at C.R. Bard as Director of Marketing, Microtek Medical Holdings Inc. as Executive Vice President of Sales & Marketing, and Covidien/Kendall-LTP as Vice President & General Manager.

Ms. Osborne holds a B.A. from Colgate University and a M.S. from New York University, Stern School of Business in New York.

About LEO Pharma Inc.

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions.

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions.

LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide.

For more information, visit http://www.leo-pharma.com and http://www.leo-pharma.us

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.